Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STA363 (lactic acid) in chronic discogenic low back pain
NCT04673461Phase 2Completed
- Sponsor
- Stayble Therapeutics
- Start
- Jul 2020
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of lactic acid in discogenic low back pain (DLBP) (3 arms), sponsored by Stayble Therapeutics. Primary endpoint: Numerical Rating Scale Pain Intensity at 6 months. Started Jul 2020; status: completed.
02
Drugs
lactic acid
03
Conditions
discogenic low back pain (DLBP)
Beyond the preview
Go deeper on NCT04673461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04673461.